Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV‐1 study
Cihan Yurdaydın(Ankara University), Jeffrey S. Glenn(Stanford Medicine), Christopher Koh(National Institutes of Health), Fatih Karakaya(Ankara University), Ramazan Idılman(Ankara University), Aysun Çalışkan(Ankara University), Çağdaş Kalkan(Ankara University), Senem Ceren Karataylı(Saarland University), Theo Heller(National Institutes of Health), Ersin Karataylı(Ankara University), Onur Keskın(Ankara University), Mithat Bozdayı(Ankara University)
Cited by 150
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2
|New England Journal of Medicine|2014|889
Immune dysregulation in human subjects with heterozygous germline mutations in <i>CTLA4</i>
|Science|2014|844
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
|Clinical Infectious Diseases|2018|726